Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469755 · ClinicalTrials.gov registry record · Phase 4
Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 302
- Enrollment target
NCT00469755: Completed Phase 4 study, sponsored by Galderma R&D.
NCT00469755 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 302 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00469755, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 302 participants
- Enrollment target
Study Summary
To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream
Interventions
- DRUG Adapalene Gel, 0.1%
- DRUG Tazarotene Cream, 0.1%
- DRUG Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
What the finished NCT00469755 record still lists
NCT00469755 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 3 interventions - of which Adapalene Gel, 0.1% is the first listed.
NCT00469755 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00469755 about?
NCT00469755 is a clinical study titled "Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne". To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream
What is the current status of trial NCT00469755?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 302 participants. The study started on 2006-02. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00469755?
The interventions under investigation include: Adapalene Gel, 0.1% (DRUG), Tazarotene Cream, 0.1% (DRUG), Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% (DRUG).
Who is sponsoring clinical trial NCT00469755?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00469755's enrollment target sits among peer trials
302 266th of 2000 higher than 1,733 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia